Results 161 to 170 of about 1,626,022 (379)
Mechanisms of alternative pre-messenger RNA splicing.
Annual Review of Biochemistry, 2003 D. Black
semanticscholar +1 more source
Targeting Lactate and Lactylation in Cancer Metabolism and Immunotherapy
Advanced Science, EarlyView.Lactate, once deemed a metabolic waste, emerges as a central regulator of cancer progression. This review elucidates how lactate and its epigenetic derivative, protein lactylation, orchestrate tumor metabolism, immune suppression, and therapeutic resistance.
Jiajing Gong +5 more
wiley +1 more source
The First Atomic Model of the Transfer-Messenger RNA in the Resume State [PDF]
, 2011 Yaser Hashem, Jie Fu, Joachim Frank
openalex +1 more source
Advanced Science, EarlyView.This study introduces MnSTF, a soft‐drug‐inspired nanoadjuvant that overcomes the systemic toxicity of STING agonists. Through Mn2+ coordination with an ENPP1 inhibitor, it enables safe cGAS‐STING activation, remodels the tumor immune microenvironment, and synergizes with radiotherapy or vaccines to elicit robust antitumor immunity.
Guangfei Sun +8 more
wiley +1 more source
1377 Messenger RNA nanoparticles targeting fusion-driven malignancies
Journal for ImmunoTherapy of Cancer, 2023 Leighton Elliott +5 more
doaj +1 more source
Single cell transcriptome analysis using next generation sequencing. [PDF]
, 2010 The heterogeneity of tissues, especially in cancer research, is a central issue in transcriptome analysis. In recent years, research has primarily focused on the development of methods for single cell analysis. Single cell analysis aims at gaining (novel)
Blattner, M.
core +1 more source
The dynamic N1-methyladenosine methylome in eukaryotic messenger RNA
Nature, 2016 D. Dominissini +19 more
semanticscholar +1 more source
Targeting DNA‐LNPs to Endothelial Cells Improves Expression Magnitude, Duration, and Specificity
Advanced Science, EarlyView.Attaching antibodies against endothelial cell surface proteins redirects the delivery and expression of DNA‐lipid nanoparticles to organs of interest. Our targeted nanoparticles enable organ‐selective DNA expression in the endothelium of the lungs, brain, or spleen, providing a therapeutic platform for dozens of endothelial‐centric diseases.
Nicolas Marzolini +24 more
wiley +1 more source
Advanced Science, EarlyView.Lenvatinib resistance poses a major challenge in advanced hepatocellular carcinoma (HCC). This study reveals that DNMT2 upregulation is a key driver, which stabilizes ACLY mRNA via m5C modification and activates the Notch signaling pathway. Crucially, combining ACLY inhibitors with lenvatinib overcomes resistance and suppresses tumors, offering a ...
Shiguang Yang +14 more
wiley +1 more source